The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Research reveals eating cheese could reduce sleep apnea risk by 28%. Here's what science says about this connection between ...

Samsung could announce its second-generation smart ring next week. Here's what I'd like to see in the Galaxy Ring 2 - and ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) machine?

We all deserve a good night's sleep, but disorders like sleep apnea can obstruct our ability to achieve great rest, TidalHealth joins us to explain more.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

CR shares expert guidance on the best sleep position, pillows, mattresses, and more if you have sleep apnea, GERD, asthma, ...

CT BUZZ Reporter Jillian Andrews recently spoke with Dr. Zubin Bham, MD a Sleep Medicine specialist from Bridgeport Hospital, about Maskless Sleep Apnea Treatments.For ...